OTCM
GSAC
Market cap247kUSD
Jul 16, Last price
0.00USD
1D
0.00%
1Q
33.33%
Jan 2017
-78.38%
Name
Gelstat Corp
Chart & Performance
P/E
—
P/S
1.65
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.14%
Rev. gr., 5y
-35.24%
Revenues
150k
+6,309.22%
Net income
-210k
L-72.40%
CFO
-106k
L-38.34%
Profile
GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation is headquartered in Palm City, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 150 6,309.22% | 2 -66.78% | ||||
Cost of revenue | 315 | 530 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (166) | (528) | ||||
NOPBT Margin | ||||||
Operating Taxes | (452) | |||||
Tax Rate | ||||||
NOPAT | (166) | (76) | ||||
Net income | (210) -72.40% | (761) 60.17% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | 66 | 102 | ||||
Long-term debt | 517 | 274 | ||||
Deferred revenue | ||||||
Other long-term liabilities | (1) | (1) | ||||
Net debt | 559 | 374 | ||||
| Cash flow | ||||||
Cash from operating activities | (106) | (172) | ||||
CAPEX | (1) | |||||
Cash from investing activities | ||||||
Cash from financing activities | 130 | 107 | ||||
FCF | (178) | 147 | ||||
| Balance | ||||||
Cash | 25 | 2 | ||||
Long term investments | ||||||
Excess cash | 18 | 2 | ||||
Stockholders' equity | (2,739) | (13,374) | ||||
Invested Capital | 2,545 | 13,031 | ||||
ROIC | ||||||
ROCE | 85.25% | 154.33% | ||||
| EV | ||||||
Common stock shares outstanding | 1,304,470 | 621,861 | ||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | (118) | (528) | ||||
EV/EBITDA | ||||||
Interest | 42 | 17 | ||||
Interest/NOPBT | ||||||